trastuzumab,tucatinib
Seagen,Roche
['mountaineer', 'optima']
#esmo22 results from mountaineer revealed tuc monotherapy and tuc + tras crossover to be well tolerated and disease stabilizing but affirmed that the optimal clinical benefit lies in a concurrent initiation of tuc + tras. exciting news for a promising combination! 